專長學科

中醫體質學、中醫病理學、中醫養生學、中西醫結合臨床研究、中醫典籍文獻研究、中醫教育結構暨課程規劃

經歷

台灣中醫醫學教育學會理事長 2017~2022

中國醫藥大學中醫學院中醫學系教授 2009/08~2021/07

台灣中醫醫史文獻學會理事長 2017~2020

台灣中醫病理學會理事長 2010~2016

台灣養生保健學會理事長 2010~2013

中國醫藥大學中醫學系系主任 2009~2012、2000~2003

中國醫藥大學中國醫學研究所所長 2008~2009

中國醫藥大學立夫中醫藥博物館館長 2003~2008

研究著作

Ho ST, Tsai YN, Su YC. The development and application of NRICM101 and NRICM102 for the treatment of COVID-19. J Formos Med Assoc. online 26 April 2023. doi: 10.1016/j.jfma.2023.04.015.
Lin JG, Huang GJ, Su YC. Efficacy analysis and research progress of complementary and alternative medicines in the adjuvant treatment of COVID-19. J Biomed Sci. 2023 May 3;30(1):30. doi: 10.1186/s12929-023-00923-5.
Lee CH, Tsai CI, Su YC, Lin SY, Lee IT, Li TC. Traditional Chinese medicine body constitution predicts new-onset diabetic albuminuria in patients with type 2 diabetes: Taichung diabetic body constitution prospective cohort study. Medicine (Baltimore). 2022 Dec 16;101(50):e32342. doi: 10.1097/MD.0000000000032342.
Chen CM, Tsai YN, Chen CH, Tseng YH, Jui-Shan Lin S, Su YC. Levonorgestrel intrauterine devices improve body constitution deviations in the perspective of traditional Chinese medicine and quality of life in patients with chronic pelvic pain and heavy menstrual bleeding. Taiwan J Obstet Gynecol. 2022 Nov;61(6):989-994. doi: 10.1016/j.tjog.2021.10.012.
Tseng YH, Lin SJ, Lee MY, Su YC. Treating COVID-19 with NRICM101 and NRICM102 - Author's reply 3. Pharmacol Res. 2022 Nov;185:106445. doi: 10.1016/j.phrs.2022.106445. Epub 2022 Sep 9.
Lee MY, Tseng YH, Lin SJ, Su YC. Treating COVID-19 with NRICM101 and NRICM102 - Author's reply 2. Pharmacol Res. 2022 Nov;185:106446. doi: 10.1016/j.phrs.2022.106446. Epub 2022 Sep 9.
Lin SJ, Lee MY, Tseng YH, Su YC. Treating COVID-19 with NRICM101 and NRICM102 - Author's reply. Pharmacol Res. 2022 Nov;185:106438. doi: 10.1016/j.phrs.2022.106438. Epub 2022 Sep 9.
Su YC, Huang GJ, Lin JG. Chinese herbal prescriptions for COVID-19 management: Special reference to Taiwan Chingguan Yihau (NRICM101). Front Pharmacol. 2022 Oct 5;13:928106. doi: 10.3389/fphar.2022.928106. eCollection 2022.
Wei WC, Liaw CC, Tsai KC, Chiou CT, Tseng YH, Chiou WF, Lin YC, Tsai CI, Lin CS, Lin CS, Liou KT, Yu IS, Shen YC, Su YC. Targeting spike protein-induced TLR/NET axis by COVID-19 therapeutic NRICM102 ameliorates pulmonary embolism and fibrosis. Pharmacol Res. 2022 Oct;184:106424. doi: 10.1016/j.phrs.2022.106424. Epub 2022 Sep 5.
Tseng YH, Lin SJ, Hou SM, Wang CH, Cheng SP, Tseng KY, Lee MY, Lee SM, Huang YC, Lin CJ, Lin CK, Tsai TL, Lin CS, Cheng MH, Fong TS, Tsai CI, Lu YW, Lin JC, Huang YW, Hsu WC, Kuo HH, Wang LH, Liaw CC, Wei WC, Tsai KC, Shen YC, Chiou WF, Lin JG, Su YC. Curbing COVID-19 progression and mortality with traditional Chinese medicine among hospitalized patients with COVID-19: A propensity score-matched analysis. Pharmacol Res. 2022 Oct;184:106412. doi: 10.1016/j.phrs.2022.106412. Epub 2022 Aug 23.

得獎事蹟

聯絡分機

E-mail